CI Global Health Sciences Corporate Class

Series A USD
As of July 21, 2023 CI Global Health Sciences Corporate Class Z (ISC 2926) (DSC 2927) (LL 2929) merged into (ISC 301) (DSC 401) (LL 1401)
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date July 1996
CAD Total net assets ($CAD)
As at 2024-06-28
$161.7 million
NAVPS
As at 2024-07-16
$42.6322
MER (%)
As at 2023-09-30
2.34
Management fee (%) 1.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.7240

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

A ISC 301
DSC SO* 401
LL SO 1401
F 324
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2024-06-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
8.19% 2.46% 1.23% 8.19% 11.15% -1.58% 5.41% 1.60% 7.99%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.7240
2021-03-26 0.2492
2020-12-18 0.3973
2020-09-25 0.3778
2020-06-26 0.2765
Payable date Total
2020-03-20 0.6464
2019-12-13 0.4049
2019-09-27 0.4529
2019-06-21 0.4275
2019-03-22 0.6736

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series A USD
As of July 21, 2023 CI Global Health Sciences Corporate Class Z (ISC 2926) (DSC 2927) (LL 2929) merged into (ISC 301) (DSC 401) (LL 1401)
 
Portfolio allocations4 As at 2024-06-30
Asset allocation (%)
  • US Equity 79.93
  • International Equity 20.12
  • Cash and Equivalents -0.05
Sector allocation (%)
  • Healthcare 96.33
  • Exchange Traded Fund 2.67
  • Consumer Services 1.05
  • Cash and Cash Equivalent -0.05
Geographic allocation(%)
  • United States 79.75
  • Denmark 8.31
  • United Kingdom 7.40
  • Germany 3.07
  • Switzerland 1.39
  • Canada 0.08
Top holdings
Sector (%)
1. Eli Lilly and Co Drugs 11.54%
2. UnitedHealth Group Inc Healthcare Services 9.73%
3. Novo Nordisk A/S Cl B Drugs 8.31%
4. AstraZeneca PLC Drugs 6.43%
5. Merck & Co Inc Drugs 6.20%
6. Humana Inc Healthcare Services 5.39%
7. Zoetis Inc Cl A Drugs 4.53%
8. Thermo Fisher Scientific Inc Healthcare Equipment 4.23%
9. Elevance Health Inc Diversified Healthcare 4.00%
10. AbbVie Inc Drugs 3.67%
11. Boston Scientific Corp Healthcare Equipment 3.27%
12. Cigna Corp Healthcare Services 3.22%
13. Siemens Healthineers AG Healthcare Equipment 3.07%
14. Stryker Corp Healthcare Equipment 2.99%
15. Intuitive Surgical Inc Healthcare Equipment 2.90%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.